MiNK Therapeutics Inc (INKT) Actualités

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

MiNK Therapeutics Reports Third Quarter 2024 Results and Business Update

NEW YORK, Nov. 14, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage...

MiNK Therapeutics to Provide Corporate Update and Third Quarter 2024 Financial Report

NEW YORK, Nov. 11, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage...

MiNK’s iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid Cancers at SITC 2024

AgenT-797 Combination with Checkpoint Inhibitors and Bispecific Engagers Expands Anti-Cancer Benefit PRAME-TCR...

Form 8-K - Current report

MiNK Therapeutics Announces Appointment of Dr. Robert Kadlec to Board of Directors

NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics (MiNK, NASDAQ: INKT), a clinical-stage company...

Form 8-K - Current report

MiNK Therapeutics and Autonomous Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors

NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics (MiNK, NASDAQ: INKT) a clinical-stage company...

MiNK Therapeutics to Present Data From iNKT Cell Programs at SITC 2024

NEW YORK, Oct. 04, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage...

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

MiNK Therapeutics to Participate in H.C. Wainwright Global Investment Conference

NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage...

Form 8-K - Current report

Form EFFECT - Notice of Effectiveness